SYNTHETIC BIOPSY
LIVE

Serial Number

90700876

Owner

Earli Inc.

Attorney

Ted D. Karr

First Use Date

Jan 4, 2023

Filing Date

May 10, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SYNTHETIC BIOPSY Trademark

Serial Number: 90700876 • Registration: 7305215

SYNTHETIC BIOPSY is a trademark filed by Earli Inc. on May 10, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Earli Inc. (9 trademarks)

Mountain View, CA 94022

Entity Type: 03

Trademark Details

Filing Date

May 10, 2021

Registration Date

February 13, 2024

First Use Anywhere

January 4, 2023

First Use in Commerce

January 24, 2023

Published for Opposition

July 26, 2022

Goods & Services

Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation

Medical services for prevention of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for prevention of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 13, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 13, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 10, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 9, 2024 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2024 CRFA
ASSIGNED TO LIE
Jan 9, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 7, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 7, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 10, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 10, 2023 GNRT
SU - NON-FINAL ACTION - WRITTEN
Apr 10, 2023 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Feb 24, 2023 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 23, 2023 AITU
USE AMENDMENT FILED
Feb 1, 2023 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 1, 2023 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 20, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 26, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 26, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 6, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 23, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 27, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 24, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 24, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 19, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 19, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 19, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2021 NWOS
NEW APPLICATION ENTERED
May 13, 2021 NWAP